Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5
作者:Fukang Yang、Lawrence B. Snyder、Anand Balakrishnan、Jeffrey M. Brown、Digavalli V. Sivarao、Amy Easton、Alda Fernandes、Michael Gulianello、Umesh M. Hanumegowda、Hong Huang、Yanling Huang、Kelli M. Jones、Yu-Wen Li、Michele Matchett、Gail Mattson、Regina Miller、Kenneth S. Santone、Arun Senapati、Eric E. Shields、Frank J. Simutis、Ryan Westphal、Valerie J. Whiterock、Joanne J. Bronson、John E. Macor、Andrew P. Degnan
DOI:10.1021/acsmedchemlett.5b00450
日期:2016.3.10
Positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 5 (mGluR5) are of interest due to their potential therapeutic utility in schizophrenia and other cognitive disorders. Herein we describe the discovery and optimization of a novel oxazolidinone-based chemotype to identify BMS-955829 (4), a compound with high functional PAM potency, excellent mGluR5 binding affinity
代谢型谷氨酸受体亚型5(mGluR5)的正变构调节剂(PAM)由于在精神分裂症和其他认知障碍中具有潜在的治疗作用而备受关注。在这里,我们描述了一种新型的基于恶唑烷酮的化学型的发现和优化,以鉴定BMS-955829(4),该化合物具有高功能性PAM效能,出色的mGluR5结合亲和力,低谷氨酸折叠移位和对mGluR5亚型的高选择性。在鉴定具有可接受的临床前安全性特征的分子时,低倍数变化和缺乏激动剂活性被证明是至关重要的。尽管折叠移位低,4在啮齿动物的移位和新物体识别模型中仍保留了功效。